PHARMACIE VOLTAIRE NATION : revenue, balance sheet and financial ratios

PHARMACIE VOLTAIRE NATION is a French company founded 14 years ago, specialized in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé. Based in PARIS (75011), this company of category PME shows in 2017 a revenue of 2.3 M€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.

Data updated on 2026-05-02

Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy

Financial history - PHARMACIE VOLTAIRE NATION (SIREN 538808015)
Indicator 2024 2023 2022 2021 2020 2019 2018 2017 2015
Revenue N/C N/C N/C N/C N/C N/C N/C 2 302 168 € 2 170 443 €
Net income 120 036 € 102 206 € 182 233 € 201 935 € 122 826 € 68 491 € 60 250 € 42 111 € 25 502 €
EBITDA N/C N/C N/C N/C N/C N/C N/C 114 629 € 99 599 €
Net margin N/C N/C N/C N/C N/C N/C N/C 1.8% 1.2%

Revenue and income statement

In 2024, PHARMACIE VOLTAIRE NATION generates positive net income of 120 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax. Change over 2015-2024: 26 k€ -> 120 k€.

Net income (2024) ?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax

120 036 €

Loading income statement...

Chart evolution

Show :

Assets

Loading data...

Liabilities

Loading data...

Solvency and debt ratios

The debt ratio (= Financial debt / Equity x 100) stands at 102%. Debt level is high: negotiating margin with banks is reduced. Financial autonomy (= Equity / Total assets x 100) reaches 43%. This high autonomy means the company finances most of its assets through equity, a sign of strength.

Debt ratio (2024) ?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low
50-100% : Moderate
> 100% : High

101.857%

Financial autonomy (2024) ?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy
20-30% : Average
< 20% : Low

42.762%

Asset age ratio (2024) ?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Interpretation
< 50% : Recent assets
50-70% : Normal wear
> 70% : Aging assets

28.6%

Solvency indicators evolution
PHARMACIE VOLTAIRE NATION

Sector positioning

Debt ratio
101.86 2024
2022
2023
2024
Q1: 16.46
Med: 58.47
Q3: 154.89
Average -6 pts over 3 years

In 2024, the debt ratio of PHARMACIE VOLTAIRE NATION (101.86) ranks above the median of the sector. This ratio measures the weight of debt relative to equity. A reduction effort could improve financial strength.

Financial autonomy
42.76% 2024
2022
2023
2024
Q1: 28.91%
Med: 49.95%
Q3: 69.47%
Average +7 pts over 3 years

In 2024, the financial autonomy of PHARMACIE VOLTAIRE NATION (42.8%) ranks below the median of the sector. This ratio represents the share of equity in total financing. An improvement would strengthen the competitive position.

Liquidity ratios

The liquidity ratio (= Current assets / Current liabilities) stands at 155.63. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.

Liquidity ratio (2024) ?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good
1-1.5 : Fair
< 1 : Liquidity risk

155.632

Liquidity indicators evolution
PHARMACIE VOLTAIRE NATION

Sector positioning

Liquidity ratio
155.63 2024
2022
2023
2024
Q1: 129.47
Med: 182.13
Q3: 260.78
Average -16 pts over 3 years

In 2024, the liquidity ratio of PHARMACIE VOLTAIRE NATION (155.63) ranks below the median of the sector. This ratio measures the ability to cover short-term debt with current assets. An improvement would strengthen the competitive position.

Working capital requirement (WCR) and payment terms

Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 146 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 634 days. Excellent situation: suppliers finance 488 days of the operating cycle (retail model).

Operating WCR (2024) ?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released
Positive = financing needed

0 €

Customer credit (2024) ?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good
45-60j : Average
> 60j : Long

146 j

Supplier credit (2024) ?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow

634 j

Inventory turnover (2024) ?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover

0 j

WCR and payment terms evolution
PHARMACIE VOLTAIRE NATION

Positioning of PHARMACIE VOLTAIRE NATION in its sector

Comparison with sector Commerce de détail de produits pharmaceutiques en magasin spécialisé

Valuation estimate

Based on 225 transactions of similar company sales in 2024, the value of PHARMACIE VOLTAIRE NATION is estimated at 1 675 791 € (range 1 166 994€ - 2 507 079€). This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.

Estimated enterprise value 2024
225 transactions
1166k€ 1675k€ 2507k€
1 675 791 € Range: 1 166 994€ - 2 507 079€
NAF 5 année 2024

Valuation method used

Net Income Multiple
120 036 € × 14.0x = 1 675 791 €
Range: 1 166 995€ - 2 507 080€

Only this financial indicator is available for this company.

Valuation evolution

How is this estimate calculated?

This estimate is based on the analysis of 225 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.

  • EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
  • Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
  • Net Income Multiple: Relevant for mature companies with stable results.

This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).

Similar companies (Commerce de détail de produits pharmaceutiques en magasin spécialisé)

Compare PHARMACIE VOLTAIRE NATION with other companies in the same sector:

Voir toutes les statistiques du secteur Commerce de détail de produits pharmaceutiques en magasin spécialisé

Frequently asked questions about PHARMACIE VOLTAIRE NATION

What is the revenue of PHARMACIE VOLTAIRE NATION ?

The revenue of PHARMACIE VOLTAIRE NATION in 2017 is 2.3 M€.

Is PHARMACIE VOLTAIRE NATION profitable?

Yes, PHARMACIE VOLTAIRE NATION generated a net profit of 120 k€ in 2024.

Where is the headquarters of PHARMACIE VOLTAIRE NATION ?

The headquarters of PHARMACIE VOLTAIRE NATION is located in PARIS (75011), in the department Paris.

Where to find the tax return of PHARMACIE VOLTAIRE NATION ?

The tax return of PHARMACIE VOLTAIRE NATION is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).

In which sector does PHARMACIE VOLTAIRE NATION operate?

PHARMACIE VOLTAIRE NATION operates in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé (NAF code 47.73Z). See the 'Sector positioning' section above to compare the company with its competitors.